Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ID-082 DDI with Midazolam in Healthy Males
NCT03363984Phase 1Completed
- Sponsor
- Idorsia
- Start
- Nov 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivasorexant in binge eating disorder (BED) and anxiety disorder, sponsored by Idorsia. Primary endpoints: Maximum Plasma Concentration (Cmax) of Midazolam at Day 11 and Area Under the Plasma Concentration-Time Curve from Time Zero to 24 Hours (AUC0-24) of Midazolam. Started Nov 2017; status: completed.
02
Drugs
nivasorexant
03
Conditions
binge eating disorder (BED)anxiety disorder
Beyond the preview
Go deeper on NCT03363984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03363984.